Koers Synthetic Biologics Inc Nyse
Aandelen
US87164U1025
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 4,11 mln. 3,79 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -28 mln. -25,84 mln. | Nettowinst (verlies) 2025 * | -34 mln. -31,37 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,29
x | K/w-verhouding 2025 * |
-0,31
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,16% |
Recentste transcriptie over Synthetic Biologics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 62 | 01-06-15 | |
Michael Kaleko
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-12 |
- | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jeff Wolf
BRD | Director/Board Member | 60 | 01-01-06 |
John Monahan
BRD | Director/Board Member | 77 | 11-11-20 |
Jeffrey Kraws
CHM | Chairman | 59 | 01-01-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,61% | 122 mld. | |
+17,75% | 112 mld. | |
+17,23% | 25,91 mld. | |
-24,11% | 19,33 mld. | |
-18,56% | 16,17 mld. | |
-18,47% | 15,56 mld. | |
-47,75% | 14,65 mld. | |
+57,35% | 14,34 mld. | |
+5,62% | 14 mld. |